Literature DB >> 18180176

Serum concentration/dose ratio of levetiracetam before, during and after pregnancy.

Andreas Austgulen Westin1, Arne Reimers, Grethe Helde, Karl Otto Nakken, Eylert Brodtkorb.   

Abstract

PURPOSE: To investigate changes in levetiracetam (LEV) serum concentration/dose ratio (C/D-ratio) in relation to pregnancy.
METHODS: Altogether 21 consecutive pregnancies in 20 women with epilepsy receiving LEV during gestation were studied retrospectively. The main target variable was the C/D-ratio before and during pregnancy, and in the post partum period. Secondary target variables were changes in LEV dose, concomitant use of other antiepileptic drugs and seizure frequency. Student's paired t-test and two-sample t-test for independent samples were used to test for statistically significant changes in C/D-ratio means.
RESULTS: Mean C/D-ratio in the third trimester was 50% of the mean C/D-ratio at baseline (p<0.001, n=11). Baseline levels were reached within the first weeks after pregnancy. The interindividual variability was pronounced.
CONCLUSIONS: Serum concentrations of LEV declined significantly in the third trimester of pregnancy and increased rapidly after delivery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18180176     DOI: 10.1016/j.seizure.2007.11.027

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  12 in total

1.  Therapeutic drug monitoring of levetiracetam in daily clinical practice: high-performance liquid chromatography versus immunoassay.

Authors:  Maria Mendoza Aguilera; María Dolores Bellés Medall; Tamara Álvarez Martín; Óscar Pascual Marmaneu; Carla Liñana Granell; Raúl Ferrando Piqueres
Journal:  Eur J Hosp Pharm       Date:  2018-10-20

Review 2.  Use of Antiepileptic Drugs During Pregnancy: Evolving Concepts.

Authors:  Page B Pennell
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

3.  Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy.

Authors:  T L Reisinger; M Newman; D W Loring; P B Pennell; K J Meador
Journal:  Epilepsy Behav       Date:  2013-08-02       Impact factor: 2.937

Review 4.  Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review.

Authors:  Gali Pariente; Tom Leibson; Alexandra Carls; Thomasin Adams-Webber; Shinya Ito; Gideon Koren
Journal:  PLoS Med       Date:  2016-11-01       Impact factor: 11.069

5.  Therapeutic levetiracetam monitoring during pregnancy: "mind the gap".

Authors:  Maya Berlin; Dana Barchel; Revital Gandelman-Marton; Nurit Brandriss; Ilan Blatt; Tomer Ziv-Baran; Miri Y Neufeld; Natalie Dinavitser; Elkana Kohn; Dotan Shaniv; Tal De-Haan; Fanny Ofek; Gideon Koren; David Stepensky; Matitiahu Berkovitch
Journal:  Ther Adv Chronic Dis       Date:  2019-05-27       Impact factor: 5.091

6.  Levetiracetam, lamotrigine and carbamazepine: which monotherapy during pregnancy?

Authors:  Luisa Mari; Fabio Placidi; Andrea Romigi; Mario Tombini; Chiara Del Bianco; Martina Ulivi; Claudio Liguori; Natalia Manfredi; Alessandro Castelli; Nicola Biagio Mercuri; Francesca Izzi
Journal:  Neurol Sci       Date:  2021-09-01       Impact factor: 3.307

7.  Antiepileptic drug clearances during pregnancy and clinical implications for women with epilepsy.

Authors:  P Emanuela Voinescu; Suna Park; Li Q Chen; Zachary N Stowe; D Jeffrey Newport; James C Ritchie; Page B Pennell
Journal:  Neurology       Date:  2018-09-05       Impact factor: 11.800

8.  Levetiracetam in the treatment of epilepsy.

Authors:  Bassel Abou-Khalil
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

9.  Are doses of lamotrigine or levetiracetam adjusted during pregnancy?

Authors:  Noni Richards; David Reith; Michael Stitely; Alesha Smith
Journal:  Epilepsia Open       Date:  2017-11-27

10.  Umbilical Cord, Maternal Milk, and Breastfed Infant Levetiracetam Concentrations Monitoring at Delivery and during Early Postpartum Period.

Authors:  Ivana Kacirova; Milan Grundmann; Hana Brozmanova
Journal:  Pharmaceutics       Date:  2021-03-17       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.